DCRE yields 4.80% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, DCRE + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DCRE + PFE for your $10,000?
DCRE offers targeted exposure to commercial real estate. The portfolio holds investment grade commercial mortgage-backed securities of any maturity or duration, including agency and non-agency CMBS, commercial real estate CLOs, and related derivatives (e.g., credit default swaps). The fund may also invest in US government-backed securities, other fixed income securities, and cash equivalents, as well as open- and closed-end investment companies and ETFs. The portfolio is managed using a controlled risk approach which involves the advisers view of potential relative performance and liquidity conditions of various market sectors, security selection within sectors, risk/reward, the shape of the yield curve, interest rate fluctuations, and current fiscal policy. The adviser intends to have a dollar-weighted average portfolio duration of three years or less. The fund may use derivatives for hedging purposes. Before February 1, 2024, the fund traded under the ticker DCMB.
Full DCRE Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.